Domain Therapeutics and Merck Serono announce an agreement to develop drugs for Parkinson’s disease
17 January 2011 | By Andrew Lloyd & Associates
Agreement covers metabotropic glutamate receptor 4 (mGluR4) Positive Allosteric Modulator (PAM) drugs targeting Parkinson's disease...